Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- NS Pharma, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 1, 2026
- Completion date
- November 1, 2028
- Enrollment
- 135 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.